Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
type: MedicalStudy
description: A Phase II Randomized, Double-Blinded Evaluation of Oral Everolimus (RAD001) Plus Bevacizumab vs. Oral Placebo Plus Bevacizumab in the Treatment of Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
status: COMPLETED
study design: INTERVENTIONAL
phase: PHASE2
start date: 2010-12-27
end date: 2015-03-23
license: https://creativecommons.org/publicdomain/zero/1.0/
source: https://clinicaltrials.gov/study/NCT00886691
source organization: US National Library of Medicine
publisher: AI Analytics
sponsor: GOG Foundation
study subject: Recurrent Fallopian Tube Carcinoma
study subject: Recurrent Ovarian Carcinoma
study subject: Recurrent Primary Peritoneal Carcinoma
keywords: PHASE2
keywords: INTERVENTIONAL
keywords: COMPLETED
keywords: Recurrent Fallopian Tube Carcinoma
keywords: Recurrent Ovarian Carcinoma
keywords: Recurrent Primary Peritoneal Carcinoma

AI Analytics
type: Organization